Masimo Receives FDA Clearance for Root Patient Monitoring Platform

Masimo announced U.S. Food and Drug Administration 510(k) clearance for the Root patient monitoring and connectivity platform.

Advertisement

The platform includes a built-in connectivity gateway through Iris for standalone devices such as IV pumps, capnography, wireless functionality as well as flexible measurement expansion through Masimo Open Connect.

“With the new FDA clearance for Root, Masimo is eager to help U.S. clinicians usher in a new era of patient care and improved patient safety with a platform that should measurably improve the performance and cost curve,” said Joe Kiani, founder and CEO of Masimo in a news release.

Masimo is a developer of noninvasive monitoring technologies.

More Articles on Quality:

Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

When nurses help build the AI, adoption follows: Lessons from 3 health systems

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Amy McCarthy, DNP, RNC-MNN, NE-BC, CENP, Hippocratic AIBeth Reimschissel, PhD, RN, CNL, Memorial HermannAllison Schlinkert, MSN, RN, NPD-BC, Cincinnati Children'sScott Estep, MBOE, BSN, RN, CSSBB, OhioHealth System

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.